Anzeige
Mehr »
Login
Samstag, 19.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Trumps Dekret beschleunigt Antimon-Boom - Wird Global Tactical der nächste Highflyer für kritische Mineralien?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

GlobeNewswire (Europe)-Archiv vom 23.05.2024

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
23.05.24Viking Supply Ships AB: Viking Supply Ships AB (publ) Interim report Q1 202466The market for AHTS-vessels started out with more activity than expected after a soft period in the fourth quarter of 2023. Contracts for some of the vessels outside the North Sea in the beginning of...
► Artikel lesen
23.05.24Irisity AB: The CEO comments on Q1 2024110Streamlining Irisity's global operations for profitability and growth.The CEO comments on Q1 2024:In Q1, we took significant steps towards profitability and growth. In the quarter, our growth initiatives...
► Artikel lesen
23.05.24Cereno Scientific AB: Cereno Scientific publishes the interim report for Q1 2024 ( January 1-March 31)35The Board and Chief Executive Officer of Cereno Scientific AB here present the interim report for Q1 2024 (January 1-March 31). Summary of the interim report for Q1 2024 (January 1-March 31) Cereno...
► Artikel lesen
23.05.24Redwood Pharma AB: Redwood Pharma provides an update on the company's future132Stockholm, 23 May 2024. Redwood Pharma AB (publ) announces today that the company is evaluating potential solutions to address its strained financial situation. This is in light of the fact that the...
► Artikel lesen
23.05.24Fragbite Group AB: Fragbite Group declares subsidiary Fall Damage Studio bankrupt151The board of directors of Fragbite Group AB publ ("Fragbite Group" or the "Company") has today, on 23 May 2024, resolved to declare bankruptcy for its subsidiary Fall Damage Studio AB ("Fall Damage")....
► Artikel lesen
23.05.24Fragbite Group AB: Marcus Teilman resigns from the position of CEO at his own request162Today, CEO Marcus Teilman informed the Board of Directors of Fragbite Group AB (publ) ("Fragbite Group" or the "Company") that he wishes to terminate his employment. The Board has accepted his request...
► Artikel lesen
23.05.24Scandion Oncology A/S: Scandion Oncology Announces The Final Terms Of The Rights Issue288On 19 April 2024, the board of directors of Scandion Oncology ("Scandion" or the "Company") resolved on the intention, subject to authorizations by the annual general meeting of the Company, to carry...
► Artikel lesen
23.05.24Nordrest Holding AB: Nordrest's offering was substantially oversubscribed - trading in the share on Nasdaq First North Growth Market commences today453THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, DISTRIBUTED OR PUBLISHES, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA...
► Artikel lesen
23.05.24ACCIONA, S.A.: Q1 2024 Trading Statement (January - March)382EXECUTIVE SUMMARY ACCIONA has begun 2024 progressing well towards its objective of installing 1.7 GW of new renewable energy capacity for the second year in a row, and achieving strong performance...
► Artikel lesen
23.05.24Millicom International Cellular S.A.: Millicom (Tigo) comments on shareholder communication436Millicom (Tigo) comments on shareholder communication Luxembourg, May 23, 2024 - The Board of Directors of Millicom International Cellular S.A. ("Millicom") confirms that it received today a non-binding...
► Artikel lesen
23.05.24Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide335Company announcement - No. 27 / 2024 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide Mean...
► Artikel lesen
23.05.24Pepco Group N.V.: Interim results for six months ended 31 March 2024276Strong H1 profit growth with tangible strategic progress Pepco Group, the fast-growing pan-European variety discount retailer, today reports interim results for the six-month period ended 31 March...
► Artikel lesen
23.05.24Coherus BioSciences, Inc.: Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting283CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells...
► Artikel lesen
23.05.24Premier Health of America Inc.: Premier Health Reports 2024 Second Quarter Results471MONTRÉAL, May 23, 2024 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the "Corporation"), a leading Canadian Healthtech company, announces it has filed its Unaudited Quarterly Consolidated...
► Artikel lesen
23.05.24Elicio Therapeutics, Inc.: Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting246ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levelsELI-002 7P generated an mKRAS-specific T...
► Artikel lesen
23.05.24Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq234New York, NY, May 23, 2024 (GLOBE NEWSWIRE) -- Fresh2 Group Ltd. (NASDAQ: FRES) ("Fresh2" or the "Company"), a B2B e-commerce and supply chain management company within the restaurant and food industry...
► Artikel lesen
23.05.24Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101360- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast...
► Artikel lesen
23.05.24Affimed N.V.: Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024247In 15 response-evaluable patients with metastatic EGFR wild-type NSCLC, who were pretreated with platinum doublet chemotherapy and checkpoint inhibitors, the combination of AFM24 and atezolizumab...
► Artikel lesen
23.05.24Elcora Advanced Materials Corp.: Elcora Announces Share Consolidation314HALIFAX, Nova Scotia, May 23, 2024 (GLOBE NEWSWIRE) -- ELCORA ADVANCED MATERIALS CORP. (TSX.V:ERA | Frankfurt:ELM | OTCQB - ECORF), (the "Company" or "Elcora"), a leading battery metals exploration...
► Artikel lesen
23.05.24NKGen Biotech, Inc.: NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting214SNK02 has the potential to be a first-in-class cryopreserved allogeneic NK cell therapy for solid tumors that does not require lymphodepletion before administration, which may lead to better overall...
► Artikel lesen
Seite:  Weiter >>